These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 18474288)

  • 1. Immunobiology of HPV and HPV vaccines.
    Stanley M
    Gynecol Oncol; 2008 May; 109(2 Suppl):S15-21. PubMed ID: 18474288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Host responses to infection with human papillomavirus.
    Stanley MA; Sterling JC
    Curr Probl Dermatol; 2014; 45():58-74. PubMed ID: 24643178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlating immunity with protection for HPV infection.
    Frazer I
    Int J Infect Dis; 2007 Nov; 11 Suppl 2():S10-6. PubMed ID: 18162240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunobiology of human papillomavirus infection and vaccination - implications for second generation vaccines.
    Stanley M; Gissmann L; Nardelli-Haefliger D
    Vaccine; 2008 Aug; 26 Suppl 10():K62-7. PubMed ID: 18847558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
    Olsson SE; Villa LL; Costa RL; Petta CA; Andrade RP; Malm C; Iversen OE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; von Krogh G; Lehtinen M; Paavonen J; Tamms GM; Giacoletti K; Lupinacci L; Esser MT; Vuocolo SC; Saah AJ; Barr E
    Vaccine; 2007 Jun; 25(26):4931-9. PubMed ID: 17499406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measuring serum antibody to human papillomavirus following infection or vaccination.
    Frazer IH
    Gynecol Oncol; 2010 Jun; 118(1 Suppl):S8-11. PubMed ID: 20494221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine.
    Villa LL
    Int J Infect Dis; 2007 Nov; 11 Suppl 2():S17-25. PubMed ID: 18162241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune control of human papillomavirus (HPV) associated anogenital disease and potential for vaccination.
    Stern PL
    J Clin Virol; 2005 Mar; 32 Suppl 1():S72-81. PubMed ID: 15753015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine.
    Giuliano AR; Lazcano-Ponce E; Villa L; Nolan T; Marchant C; Radley D; Golm G; McCarroll K; Yu J; Esser MT; Vuocolo SC; Barr E
    J Infect Dis; 2007 Oct; 196(8):1153-62. PubMed ID: 17955433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.
    Stanley M; Lowy DR; Frazer I
    Vaccine; 2006 Aug; 24 Suppl 3():S3/106-13. PubMed ID: 16949996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virus-like particle vaccines and adjuvants: the HPV paradigm.
    Buonaguro FM; Tornesello ML; Buonaguro L
    Expert Rev Vaccines; 2009 Oct; 8(10):1379-98. PubMed ID: 19803760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant vaccines for the prevention of human papillomavirus infection and cervical cancer.
    Palmer KE; Jenson AB; Kouokam JC; Lasnik AB; Ghim SJ
    Exp Mol Pathol; 2009 Jun; 86(3):224-33. PubMed ID: 19454268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
    Seo SH; Jin HT; Park SH; Youn JI; Sung YC
    Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune responses to human papillomavirus.
    Stanley M
    Vaccine; 2006 Mar; 24 Suppl 1():S16-22. PubMed ID: 16219398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HPV: from infection to cancer.
    Stanley MA; Pett MR; Coleman N
    Biochem Soc Trans; 2007 Dec; 35(Pt 6):1456-60. PubMed ID: 18031245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Use of Both Therapeutic and Prophylactic Vaccines in the Therapy of Papillomavirus Disease.
    Garbuglia AR; Lapa D; Sias C; Capobianchi MR; Del Porto P
    Front Immunol; 2020; 11():188. PubMed ID: 32133000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human papillomavirus type 58 L1 virus-like particles purified by two-step chromatography elicit high levels of long-lasting neutralizing antibodies.
    Xie X; Liu Y; Zhang T; Xu Y; Bao Q; Chen X; Liu H; Xu X
    Arch Virol; 2013 Jan; 158(1):193-9. PubMed ID: 22965579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protecting the next generation: what is the role of the duration of human papillomavirus vaccine-related immunity?
    Günther OP; Ogilvie G; Naus M; Young E; Patrick DM; Dobson S; Duval B; Noël PA; Marra F; Miller D; Brunham RC; Pourbohloul B
    J Infect Dis; 2008 Jun; 197(12):1653-61. PubMed ID: 18513154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction and characterization of recombinant fowlpox viruses expressing human papilloma virus E6 and E7 oncoproteins.
    Pozzi E; Basavecchia V; Zanotto C; Pacchioni S; Morghen Cde G; Radaelli A
    J Virol Methods; 2009 Jun; 158(1-2):184-9. PubMed ID: 19428588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GARDASIL: prophylactic human papillomavirus vaccine development--from bench top to bed-side.
    Shi L; Sings HL; Bryan JT; Wang B; Wang Y; Mach H; Kosinski M; Washabaugh MW; Sitrin R; Barr E
    Clin Pharmacol Ther; 2007 Feb; 81(2):259-64. PubMed ID: 17259949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.